COMPARISON OF THE EFFICACY BETWEEN PREOPERATIVE CALCIUM & VITAMIN D3 VERSUS CALCIUM SUPPLEMENTATION ALONE TO PREVENT POST OPERATIVE SYMPTOMATIC HYPOCALCEMIA AFTER TOTAL THYROIDECTOMY IN EUTHYROID PATIENTS

NCT07597096 | Not Yet Recruiting DMC

• 1 other identifier: Dr Ali Raza
• Study Type: interventional
• Target: 124
• Locations: 1 country
• Sites: 1

Brief Summary

Total thyroidectomy is a commonly performed surgery for thyroid diseases such as multinodular goiter. One of the most frequent complications after this procedure is hypocalcemia (low blood calcium levels), which may cause symptoms such as tingling around the mouth, muscle cramps, and in severe cases, spasms or confusion. This condition usually occurs within the first 24-72 hours after surgery and may delay hospital discharge and increase patient discomfort. This study aims to compare the effectiveness of preoperative calcium plus vitamin D3 supplementation versus calcium supplementation alone in preventing postoperative symptomatic hypocalcemia in patients undergoing total thyroidectomy. Patients diagnosed with multinodular goiter and planned for surgery will be randomly assigned into two groups. One group will receive calcium with vitamin D3 for seven days before surgery, while the other group will receive calcium alone for the same duration. After surgery, patients will be monitored for symptoms of hypocalcemia and their serum calcium levels will be checked at 6, 24, and 48 hours, as well as at a follow-up visit on day 14. The main outcome of the study is the occurrence of symptomatic hypocalcemia in both groups. The results of this study may help determine whether adding vitamin D3 to preoperative calcium supplementation provides better protection against hypocalcemia after thyroid surgery, potentially improving patient outcomes and reducing hospital stay.

Conditions

Postoperative Symptomatic Hypocalcemia Following Total Thyroidectomy

Keywords

Total thyroidectomy Postoperative hypocalcemia Symptomatic hypocalcemia Calcium supplementation Vitamin D3 (cholecalciferol) Preoperative supplementation

Outcome Measures

Primary Outcomes (1)

• Incidence of postoperative symptomatic hypocalcemia

  3 month

Study Arms (2)

Preoperative Calcium and Vitamin D3 Supplementation

ACTIVE COMPARATOR

Participants in this arm will receive oral calcium carbonate (500-1000 mg, two to three times daily) along with oral vitamin D3 (cholecalciferol 1000-2000 IU once daily) for 7 days prior to total thyroidectomy. This supplementation is given to assess its effectiveness in reducing postoperative symptomatic hypocalcemia compared to calcium alone.

Drug: Calcium carbonate plus vitamin D3 (cholecalciferol)

Participants in this arm will receive oral calcium carbonate (500-1000 mg, two to three times daily)

ACTIVE COMPARATOR

Participants in this arm will receive oral calcium carbonate (500-1000 mg, two to three times daily) for 7 days prior to total thyroidectomy without vitamin D3 supplementation. This group serves as the control to compare the incidence of postoperative symptomatic hypocalcemia.

Drug: Calcium carbonate plus vitamin D3 (cholecalciferol)

Interventions

Calcium carbonate plus vitamin D3 (cholecalciferol) DRUG

Participants in this arm will receive oral calcium carbonate (500-1000 mg, two to three times daily) in combination with oral vitamin D3 (cholecalciferol 1000-2000 IU once daily) for 7 days prior to total thyroidectomy. This preoperative supplementation is administered to evaluate its effectiveness in reducing the incidence of postoperative symptomatic hypocalcemia.

Participants in this arm will receive oral calcium carbonate (500-1000 mg, two to three times daily); Preoperative Calcium and Vitamin D3 Supplementation

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A) Age between 18 to 60 years B) Both genders C) Multiple nodular goiter diagnosed on the basis of history and investigation like thyroid function test , USG neck for TIRADS scoring and USG guided FNAC to confirm the diagnosis .
• D) ASA grade 1 \&2 E) With preserved one or two parathyroid gland

You may not qualify if:

• A) Cardiovascular disease B) Deranged Renal parameters C) Pregnancy D) Concomitant endocrine pathology warranting the surgery

Sponsors & Collaborators

• Mayo Hospital Lahore: collaborator
• King Edward Medical University: lead

Study Sites (1)

King Edward Medical University

Lahore, Punjab Province, 54000, Pakistan

Location

Related Links

• Database of peer-reviewed studies on thyroidectomy and postoperative hypocalcemia.

MeSH Terms

Interventions

Calcium Carbonate; Cholecalciferol

Intervention Hierarchy (Ancestors)

Calcium Compounds; Inorganic Chemicals; Carbonates; Carbonic Acid; Carbon Compounds, Inorganic; Minerals; Cholestenes; Cholestanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Sterols; Vitamin D; Secosteroids; Membrane Lipids; Lipids

Study Officials

• Ahmad Rauf, MBBS

  KEMU

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ali Raza, MBBS

CONTACT

+923406600052; dralirazasial777@gmail.com

Ahmad Rauf, MBBS

CONTACT

+923006023465; ahmadrauf498@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Participants will be randomly assigned into two parallel groups. Group A will receive preoperative oral calcium with vitamin D3 supplementation, while Group B will receive oral calcium supplementation alone. Outcomes will be compared between the two groups after total thyroidectomy.

Study Record Dates

• First Submitted: May 13, 2026
• First Posted: May 19, 2026
• Study Start: May 10, 2026
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): June 30, 2026
• Last Updated: May 19, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)